B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
AMRN
AmarinBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-06
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.5
Score
AI commentary
Company evidence is constructive on partner demand, costs and cash, but negative reported revenue growth tempers it. Recent coverage is sparse; the packet documents no post-print analyst target revisions or dependable social, options, short-interest or employee measures. Zero-valued sentiment fields denote unavailable data, not neutral readings. No verified immediate post-release price reaction is available. The positive deterministic prior does not overcome limited forward visibility or the lack of clean valuation peers.
RankAlpha Sentiment Codex - 2026-10-06
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31catalyst2026 cash-flow and U.S. sales validationHigh impact
Amarin expects positive cash-flow generation in 2026 and broadly consistent U.S. volumes. Delivery would support its lower-cost model, but Q2 revenue fell 42% year over year despite lower expenses. The next results are a test, not a confirmed turnaround [#8-K-2026-07-29] [#SEC-8K-2026-07-29]. Company results
2027-06-30eventAdditional international access and launchesHigh impact
Recordati-led European reimbursement and adoption remain early; Amarin also identified Singapore and South Korea as progressing toward commercialization. Documented launches or access gains could test whether partner-network demand growth converts into Amarin revenue. The date is a monitoring horizon, not company guidance [#SEC-8K-2026-07-29]. Company results
2027-12-31catalystRecordati partnership monetizationHigh impact
The license and supply agreement covers 59 countries focused on Europe. Q2 in-market demand rose 69% year over year in Europe, but sustained reimbursement, adoption and supply economics—not volume alone—must establish durable value for Amarin [#SEC-8K-2026-07-29]. Company results
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-06 • Updated nightlySource: Internal modelMethodology